By Dr Charlotte Rose Lemech

Journal articles

Lee DH; Roohullah A; Cho BC; Lemech C; de Souza P; Millward M; Choi J; Park KE; Lee M; Kim Y; Park S; Lee J; Kim J; Shin YK; Han J-Y, 2021, 'Phase I dose-escalation study to evaluate safety and clinical activity of c-MET inhibitor ABN401 in patients with advanced solid tumor', ANNALS OF ONCOLOGY, 32, pp. S1029 - S1030, http://dx.doi.org/10.1016/j.annonc.2021.08.1958

Lickliter JD; Jennens R; Lemech CR; Kichenadasse G; Cai D; Su SY-C, 2021, 'Phase 1 dose-escalation study of ACT001 in patients with recurrent glioblastoma and other advanced solid tumors.', Journal of Clinical Oncology, 39, pp. 2037 - 2037, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.2037

Coward J; Mislang ARA; Frentzas S; Lemech CR; Nagrial A; Jin X; Li B; Wang ZM; Kwek KY; Xia Y, 2021, 'Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.', Journal of Clinical Oncology, 39, pp. 2515 - 2515, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.2515

Lemech CR; Kichenadasse G; Marschner J-P; Alevizopoulos K; Otterlei M; Millward M, 2021, 'Safety profile and disease stabilization in late stage, heavily pretreated, solid tumor patients in a first-in-human (FIH) study of ATX-101, a drug targeting proliferating cell nuclear antigen (PCNA).', Journal of Clinical Oncology, 39, pp. 3067 - 3067, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.3067

Lee DH; Roohullah A; Cho BC; Lemech CR; de Souza PL; Millward M; Choi JY; Park KE; Lee M; Kim Y; Shin Y; Han J-Y, 2021, 'Trial in progress: A phase 1-2 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors.', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.TPS3157

Coward J; Frentzas S; Mislang A; Gao B; Lemech C; Jin X; Li B; Wang M; Kwek KY; Zhou Y; Xia Y, 2021, '427 Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study', Regular and Young Investigator Award Abstracts, pp. A457 - A457, http://dx.doi.org/10.1136/jitc-2021-sitc2021.427

Lemech C; Woodward N; Chan N; Mortimer J; Naumovski L; Nuthalapati S; Tong B; Jiang F; Ansell P; Ratajczak CK; Sachdev J, 2020, 'A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors', Investigational New Drugs, 38, pp. 1815 - 1825, http://dx.doi.org/10.1007/s10637-020-00960-z

Perry N; Moss S; Dixon S; Milner S; Mokbel K; Lemech C; Arkenau HT; Duffy S; Pinker K, 2020, 'Mammographic breast density and urbanization: Interactions with BMI, environmental, lifestyle, and other patient factors', Diagnostics, 10, http://dx.doi.org/10.3390/diagnostics10060418

Coward J; Lemech CR; Mislang ARA; Parakh S; Underhill C; Nagrial A; Jin X; Li B; Wang ZM; Kwek KY; Xia Y, 2020, 'A phase I study of AK112, a bispecific antibody that targets PD-1 and VEGF co-expressing T cells, in patients with advanced solid tumors.', Journal of Clinical Oncology, 38, pp. TPS3155 - TPS3155, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps3155

Berry S; Giraldo N; Nguyen P; Green B; Xu H; Ogurtsova A; Soni A; Succaria F; Wang D; Roberts C; Stein J; Engle E; Pardoll D; Anders R; Cottrell T; Taube JM; Tran B; Voskoboynik M; Kuo J; Bang YL; Chung HC; Ahn MJ; Kim SW; Perera A; Freeman D; Achour I; Faggioni R; Xiao F; Ferte C; Lemech C; Meric-Bernstam F; Werner T; Hodi S; Messersmith W; Lewis N; Talluto C; Dostalek M; Tao A; McWhirter S; Trujillo D; Luke J; Xu C; Bomarelli B; Qi J; Qin G; Yu H; Jenkins M; Lo KM; Halle JP; Lan Y; Taylor M; Vogelzang N; Cohn A; Stepan D; Shumaker R; Dutcus C; Guo M; Schmidt E; Rasco D; Brose M; Di Simone C; Jain S; Richards D; Encarnacion C; Vogelzeng N; Mier J; An J; Yang YY; Lee WH; Yang J; Kim JK; Kim HG; Paek SH; Lee JW; Woo J; Kim JB; Kwon H; Lim W; Paik NS; Kim YK; Moon BI; Janku F; Tan D; Martin-Liberal J; Takahashi S; Geva R; Gucalp A; Chen X; Subramanian K; Mataraza J; Wheler J; Bedard P, 2019, 'Correction: 33rd Annual meeting & pre-conference programs of the Society for Immunotherapy of Cancer (SITC 2018) (Journal for ImmunoTherapy of Cancer (2018) 6:Suppl 1 DOI: 10.1186/s40425-018-0422-y)', Journal for Immunotherapy of Cancer, 7, http://dx.doi.org/10.1186/s40425-019-0519-y

Coward J; Lemech C; Meniawy T; Dupont CD; Gonzalez AM; Lim M; Savitsky D; Carini M; Hu S; Shebanova O; Dow E; Ortuzar W; Buell JS; Stein RB; Youssoufian H, 2018, 'Phase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors', Annals of oncology : official journal of the European Society for Medical Oncology, 29, pp. viii417, http://dx.doi.org/10.1093/annonc/mdy288.041

Lickliter JD; Jennens R; Lemech CR; Su SY-C; Chen Y, 2018, 'Phase 1 dose-escalation study of ACT001 in patients with recurrent glioblastoma and other advanced solid tumors', JOURNAL OF CLINICAL ONCOLOGY, 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.e14048

Mateo J; Ganji G; Lemech C; Burris HA; Han SW; Swales K; Decordova S; DeYoung MP; Smith DA; Kalyana-Sundaram S; Wu J; Motwani M; Kumar R; Tolson JM; Rha SY; Chung HC; Eder JP; Sharma S; Bang YJ; Infante JR; Yan L; De Bono JS; Arkenau HT, 2017, 'A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors', Clinical Cancer Research, 23, pp. 5981 - 5992, http://dx.doi.org/10.1158/1078-0432.CCR-17-0725

Goldstein D; Lemech C; Valle J, 2017, 'New molecular and immunotherapeutic approaches in biliary cancer', ESMO Open, 2, pp. e000152, http://dx.doi.org/10.1136/esmoopen-2016-000152

Uccello M; Moschetta M; Mak G; Martynyuk N; Hauser J; Bassett S; Voskoboynik M; Lemech C; Rafii S; Arkenau H-T, 2017, 'BRAF +/- MEK inhibition in patients (pts) with BRAF-mutant (mut) metastatic colorectal cancer (mCRC): The Sarah Cannon Research Institute UK’s experience.', Journal of Clinical Oncology, 35, pp. 645 - 645, http://dx.doi.org/10.1200/jco.2017.35.4_suppl.645

Soria JC; Gan HK; Blagden SP; Plummer R; Arkenau HT; Ranson M; Evans TRJ; Zalcman G; Bahleda R; Hollebecque A; Lemech C; Dean E; Brown J; Gibson D; Peddareddigari V; Murray S; Nebot N; Mazumdar J; Swartz L; Auger KR; Fleming RA; Singh R; Millward M, 2016, 'A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors', Annals of Oncology, 27, pp. 2268 - 2274, http://dx.doi.org/10.1093/annonc/mdw427

Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; De Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG, 2016, 'Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma', Blood, 128, pp. 1821 - 1828, http://dx.doi.org/10.1182/blood-2016-07-726729

Hughes A; Landers D; Arkenau HT; Shah S; Stephens R; Mahal A; Simmons M; Lemech C; Royle J, 2016, 'Erratum to: Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT (Adv Ther, (2016), 33, (1012-1024), 10.1007/s12325-016-0335-4)', Advances in Therapy, 33, pp. 1677 - 1678, http://dx.doi.org/10.1007/s12325-016-0390-x

Lemech CR; Williams R; Thompson SR; McCaughan B; Chin M, 2016, 'Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: A case report', BMC Research Notes, 9, pp. 386, http://dx.doi.org/10.1186/s13104-016-2189-x

Lemech CR; Ensell L; Paterson JC; Eminowicz G; Lowe H; Arora R; Arkenau HT; Widschwendter M; MacDonald N; Olaitan A; Mould T; Meyer T; Hartley J; Mitra A; Ledermann JA; McCormack M; Kristeleit RS, 2016, 'Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer', Oncology Switzerland, 91, pp. 48 - 54, http://dx.doi.org/10.1159/000445999

Hughes A; Landers D; Arkenau HT; Shah S; Stephens R; Mahal A; Simmons M; Lemech C; Royle J, 2016, 'Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT', Advances in Therapy, 33, pp. 1012 - 1024, http://dx.doi.org/10.1007/s12325-016-0335-4

Bendell JC; Patel MR; Yoshida K; Seraj J; Weaver R; Lemech C; Todaro TG; Pant S; Arkenau HT, 2016, 'Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors', Cancer Chemotherapy and Pharmacology, 77, pp. 1275 - 1283, http://dx.doi.org/10.1007/s00280-016-3031-9

Laille E; Patel M; Jones SF; Burris HA; Infante J; Lemech C; Liu L; Arkenau HT, 2015, 'Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer', Journal of Clinical Pharmacology, 55, pp. 1378 - 1385, http://dx.doi.org/10.1002/jcph.560

Lemech C; Dua D; Newmark J; Saggese M; Simmons E; Spiliopoulou P; Arkenau HT, 2015, 'Patients' perceptions of research biopsies in phase i oncology trials', Oncology Switzerland, 88, pp. 95 - 102, http://dx.doi.org/10.1159/000368161

Plesner T; Arkenau H-T; Lokhorst HM; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Ahmadi T; Yeh H; Guckert ME; Feng H; Brun NC; Lisby S; Basse L; Palumbo A; Richardson PG, 2014, 'Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma', BLOOD, 124, http://dx.doi.org/10.1182/blood.V124.21.84.84

Hillman RJ; Garland SM; Gunathilake MPW; Stevens M; Kumaradevan N; Lemech C; Ward RL; Meagher A; McHugh L; Jin F; Carroll S; Goldstein D; Grulich AE; Tabrizi SN, 2014, 'Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers', International Journal of Cancer, 135, pp. 996 - 1001, http://dx.doi.org/10.1002/ijc.28730

Baird RD; Cresti N; Beddowes E; Saggese M; Flynn M; Corbacho JG; Gao F; Lemech C; Donaldson K; Posner J; Kawabata I; Forster M; Arkenau HT; Plummer R; Jodrell D; Spicer J, 2013, 'Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer', CANCER RESEARCH, 73, http://dx.doi.org/10.1158/0008-5472.SABCS13-P4-12-24

Jones A; Teschendorff AE; Li Q; Hayward JD; Kannan A; Mould T; West J; Zikan M; Cibula D; Fiegl H; Lee SH; Wik E; Hadwin R; Arora R; Lemech C; Turunen H; Pakarinen P; Jacobs IJ; Salvesen HB; Bagchi MK; Bagchi IC; Widschwendter M, 2013, 'Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development', Plos Medicine, 10, http://dx.doi.org/10.1371/journal.pmed.1001551

Saggese M; Dua D; Simmons E; Lemech C; Arkenau H-T, 2013, 'Research biopsies in the context of early phase oncology studies: clinical and ethical considerations', Oncology Reviews, pp. e5 - e5, http://dx.doi.org/10.4081/oncol.2013.232

Lemech CR; Arkenau HT, 2013, 'The future is here: Tumour profiling in day-to-day clinical practice', Drug Discovery Today, 18, pp. 689 - 691, http://dx.doi.org/10.1016/j.drudis.2013.06.006

Lemech C; Infante J; Arkenau HT, 2013, 'Combination molecularly targeted drug therapy in metastatic melanoma: Progress to date', Drugs, 73, pp. 767 - 777, http://dx.doi.org/10.1007/s40265-013-0049-8

Lemech CR; Arkenau HT, 2013, 'Rationally Designed Drug Development beyond BRAF Inhibition in Metastatic Cutaneous Melanoma', World Journal of Cancer Research

Saggese M; Dua D; Simmons E; Lemech C; Arkenau HT, 2013, 'Research biopsies in the context of early phase oncology studies: Clinical and ethical considerations', Oncology Reviews, 7, pp. 34 - 37, http://dx.doi.org/10.4081/oncol.2013.e5

Arkenau H-T; Saggese M; Lemech C, 2012, 'DABRAFENIB MESYLATE Serine/Threonine-Protein Kinase B-raf Inhibitor, Oncolytic', DRUGS OF THE FUTURE, 37, pp. 469 - 474, http://dx.doi.org/10.1358/dof.2012.037.07.1820872

Soria J-C; Gan HK; Arkenau H-T; Blagden SP; Plummer R; Ranson M; Evans TRJ; Zalcman G; Bahleda R; Hollebecque A; Lemech C; Brown J; Peddareddigari VGR; Gibson D; Murray SC; Nebot N; Mazumdar J; Fleming RA; Millward M, 2012, 'Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.', Journal of Clinical Oncology, 30, pp. 3000 - 3000, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.3000

Lemech CR; Fontela A; Arkenau H-T; Chin MTM; Li S; Liauw WS; Thomas D; De Souza PL, 2012, 'Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours.', Journal of Clinical Oncology, 30, pp. e13585 - e13585, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e13585

Arkenau HT; Saggese M; Lemech C, 2012, 'Advanced gastric cancer: Is there enough evidence to call second-line therapy standard?', World Journal of Gastroenterology, 18, pp. 6376 - 6378, http://dx.doi.org/10.3748/wjg.v18.i44.6376

Arkenau HT; Saggese M; Lemech C, 2012, 'Dabrafenib mesylate: Serine/threonine-protein kinase B-raf inhibitor oncolytic', Drugs of the Future, 37, pp. 469 - 474, http://dx.doi.org/10.1358/dof.2012.037.07.1820872

Lemech C; Arkenau HT, 2012, 'Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities', Clinical Medicine Insights Oncology, 6, pp. 53 - 66, http://dx.doi.org/10.4137/CMO.S5855

Lemech C; Infante J; Arkenau HT, 2012, 'The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: Rationale and latest evidence', Therapeutic Advances in Medical Oncology, 4, pp. 61 - 73, http://dx.doi.org/10.1177/1758834011432949

Arkenau, H.-T. ; Saggese, M. ; Lemech, C. , 2012, 'Dabrafenib. Serine/threonine-protein kinase B-raf inhibitor, Oncolitic.', Drugs of the Future, 37, pp. 0469 - 0469, http://dx.doi.org/10.1358/dof.2012.37.7.1820872

Lemech C; Arkenau HT, 2011, 'Biomarkers in advanced colorectal cancer: Challenges in translating clinical research into practice', Cancers, 3, pp. 1844 - 1860, http://dx.doi.org/10.3390/cancers3021844

Anglesio M; Kulbe H; Friedlander M; Rischin D; Lemech C; Power J; Coward J; Cowin P; House CM; Chakravarty P; Gorringe K; Campbell I; George J, 2011, 'IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.', Clinical Cancer Research, 17, pp. 2538 - 2548

Conference Papers

Lemech C; Wei J; O’Neill S; Huang N; Goh J; McCarthy N; Park JJ; Parsonson A; Xu T, 2024, '1496 JSKN033, an innovative subcutaneous-injected fixed-dose combination (FDC) of biparatopic anti-HER2 antibody drug conjugate (ADC) and PD-L1 inhibitor in advanced solid tumor', in Late-Breaking Abstracts, BMJ Publishing Group Ltd, pp. A1725 - A1725, presented at SITC 39th Annual Meeting (SITC 2024) Late Breaking Abstracts, http://dx.doi.org/10.1136/jitc-2024-sitc2024.1496

Fu S; Mckean M; Falchook GS; Barve M; Chee C-E; Lemech C; Tan TJ; Meniawy T; Hernandez-Guerrero T; Wang W; Baakili A; Marina N; Abbadessa G; Gastine S; Wang R; Calvo E, 2024, '196 Utilizing pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers to support recommended phase 2 dose (RP2D) selection for phase 1 study of SAR444245 (SAR’245) in patients with advanced solid tumors', in Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, pp. A224 - A224, presented at SITC 39th Annual Meeting (SITC 2024) Abstracts, http://dx.doi.org/10.1136/jitc-2024-sitc2024.0196

To MD; Merchant R; Atkinson V; Bedard P; Brenner W; Coello M; Antras JF; Galligan C; Lemech C; Lloyd P; Karanam SM; Margolin K; Mathew M; Prawira A; Thomas S; Twardowski P; Yavari A; Merchant F, 2023, '760 Interim PK/PD, safety and efficacy data of monotherapy dose escalation of a phase 1/2 study with MDNA11 in patients with advanced solid tumors', in Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, pp. A856 - A856, presented at SITC 38th Annual Meeting (SITC 2023) Abstracts, http://dx.doi.org/10.1136/jitc-2023-sitc2023.0760

Lee DH; Roohullah A; Cho BC; Lemech CR; De Souza PL; Millward M; Choi JY; Park KE; Kim NY; Kim E; Lee S; Kim Y; Shin Y; Han J-Y, 2022, 'A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

To M; Merchant N; Coello M; Galligan C; Mehta K; Atkinson V; Bexon M; Coward J; Lee J; Lemech C; Lloyd P; Antras J; Yavari A; Merchant F, 2022, '743 Pharmacokinetic and pharmacodynamic profile of a first-in-human study with MDNA11, an engineered long-acting beta-only IL-2 agonist', in Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, pp. A776 - A776, presented at SITC 37th Annual Meeting (SITC 2022) Abstracts, http://dx.doi.org/10.1136/jitc-2022-sitc2022.0743

To M; Merchant F; Atkinson V; Bexon M; Coward J; Lee J; Lemech C; Antras J; Lloyd P; Yavari A; Coello M; Merchant N, 2022, '744 Interim single-agent safety and anti-tumor activity from dose escalation phase of ABILITY study on MDNA11, a long-acting beta-only IL-2 agonist', in Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, pp. A777 - A777, presented at SITC 37th Annual Meeting (SITC 2022) Abstracts, http://dx.doi.org/10.1136/jitc-2022-sitc2022.0744

White S; Lemech C; Hari R; Kruger N; McLachlan G; Demaison C; Mercuri F, 2022, 'Safety and Tolerability of the Toll-Like Receptor (TLR)2/6 Agonist INNA-051 in Healthy Adults', in B31. IMMUNE CELLS AND INFLAMMATORY PATHWAYS DRIVING LUNG INJURY AND INFECTION - VIEWS FROM THE BENCH, American Thoracic Society, pp. A2598 - A2598, presented at American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA, http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2598

Back to profile page